Early Phase 1 Alzheimer's Disease Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged between 50 and 90 years old at the time of joining, of any gender
• People who have been diagnosed with probable Alzheimer's disease based on recognised international diagnostic guidelines
• People whose Alzheimer's disease falls within a moderate range, as measured by standard dementia rating scales used by doctors
• People who have had brain imaging or spinal fluid tests showing results consistent with Alzheimer's disease
• People who score between 12 and 26 on a standard memory and thinking test called the MMSE
• People who are able to read and write, or who have completed at least 4 to 6 years of formal schooling
• People who, if taking medications for mood, behaviour, or memory, have been on a stable dose of those medications for at least 3 months before joining, with no changes planned during the study; other non-Alzheimer's medications must have been stable for at least 4 weeks before the start of the study
• People who have a trusted family member, carer, or legal guardian who is able to spend at least 8 hours per week with them throughout the study
• People who are willing to take part, keep their current treatments unchanged during the study, and who have signed a consent form agreeing to participate

Who may not be able to join:

• People experiencing psychiatric or behavioural symptoms that are not typically associated with Alzheimer's disease
• People who have had a mini-stroke, stroke, or seizure within the past 12 months
• People with a known allergy to the study drug (gantenerumab) or its ingredients, or who have had a severe allergic reaction to similar types of medicines called monoclonal antibodies
• People with serious heart conditions such as severe irregular heartbeat, poorly controlled high blood pressure (above certain levels), or active stomach or bowel conditions such as peptic ulcers or inflammatory bowel disease
• People who are unable to have an MRI scan, for example because they have a pacemaker, defibrillator, or certain metal implants in their body
• People whose MRI scan shows brain changes that suggest a type of dementia other than Alzheimer's disease
• People whose MRI scan shows certain significant brain abnormalities, such as large areas of bleeding, swelling, damage, abnormal blood vessels, infection, major stroke damage, significant white matter disease, or brain tumours (confirm with trial site regarding any small cysts or benign growths)
• People who are currently taking part in another clinical trial aimed at treating or improving Alzheimer's disease
• People with any other unstable or poorly managed health condition that the study doctors believe could affect their safety or the reliability of study results
• People excluded for any other reason determined by the study doctors

Important: Always verify eligibility with the trial site directly before applying.